287 related articles for article (PubMed ID: 24343726)
1. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
Lu E; Wang BW; Alwan S; Synnes A; Dahlgren L; Sadovnick AD; Tremlett H
CNS Drugs; 2014 Feb; 28(2):89-94. PubMed ID: 24343726
[TBL] [Abstract][Full Text] [Related]
2. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis.
Thomas RH; Wakefield RA
Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835
[TBL] [Abstract][Full Text] [Related]
3. Recognizing and overcoming potential barriers to oral medications for MS.
Moses H
J Clin Psychiatry; 2014 Oct; 75(10):e28. PubMed ID: 25373133
[TBL] [Abstract][Full Text] [Related]
4. In the coming year we should abandon interferons and glatiramer acetate as first-line therapy for MS: yes.
Fox RJ
Mult Scler; 2013 Jan; 19(1):24-5. PubMed ID: 23303880
[No Abstract] [Full Text] [Related]
5. Drugs: An injection of hope.
Graham-Rowe D
Nature; 2012 Apr; 484(7393):S4. PubMed ID: 22509505
[No Abstract] [Full Text] [Related]
6. Oral treatment for multiple sclerosis.
Killestein J; Rudick RA; Polman CH
Lancet Neurol; 2011 Nov; 10(11):1026-34. PubMed ID: 22014437
[TBL] [Abstract][Full Text] [Related]
7. Emerging oral drugs for multiple sclerosis.
Gasperini C; Cefaro LA; Borriello G; Tosto G; Prosperini L; Pozzilli C
Expert Opin Emerg Drugs; 2008 Sep; 13(3):465-77. PubMed ID: 18764723
[TBL] [Abstract][Full Text] [Related]
8. Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.
Gold R
CNS Drugs; 2011 Jan; 25(1):37-52. PubMed ID: 21128693
[TBL] [Abstract][Full Text] [Related]
9. [Disease modifying drugs in multiple sclerosis and pregnancy].
Tur C; Tintoré M; Aguilera C
Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
[No Abstract] [Full Text] [Related]
10. What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question.
Pistono C; Osera C; Boiocchi C; Mallucci G; Cuccia M; Bergamaschi R; Pascale A
Pharmacol Res; 2017 Jun; 120():279-293. PubMed ID: 28396093
[TBL] [Abstract][Full Text] [Related]
11. The future of multiple sclerosis therapy.
Kieseier BC; Wiendl H; Hartung HP; Stüve O
Pharmacol Res; 2009 Oct; 60(4):207-11. PubMed ID: 19717009
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
[TBL] [Abstract][Full Text] [Related]
13. [Emerging therapies for multiple sclerosis].
de Lorenzo-Pinto A; Rodríguez-González CG; Ais-Larisgoitia A
Med Clin (Barc); 2013 Jan; 140(2):76-82. PubMed ID: 22766059
[TBL] [Abstract][Full Text] [Related]
14. [Oral treatments in multiple sclerosis].
Meca-Lallana JE; Hernández-Clares R; Carreón-Guarnizo E
Med Clin (Barc); 2014 Dec; 143 Suppl 3():23-9. PubMed ID: 25732946
[TBL] [Abstract][Full Text] [Related]
15. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
16. Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.
Desai RJ; Mahesri M; Gagne JJ; Hurley E; Tong A; Chitnis T; Minden S; Spettell CM; Matlin OS; Shrank WH; Choudhry NK
J Manag Care Spec Pharm; 2019 Jan; 25(1):113-121. PubMed ID: 30589630
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic approach to multiple sclerosis by novel oral drug.
Jadidi-Niaragh F; Mirshafiey A
Recent Pat Inflamm Allergy Drug Discov; 2011 Jan; 5(1):66-80. PubMed ID: 21184668
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and safety of oral agents for the treatment of relapsing-remitting multiple sclerosis.
Guarnera C; Bramanti P; Mazzon E
Drug Des Devel Ther; 2017; 11():2193-2207. PubMed ID: 28814828
[TBL] [Abstract][Full Text] [Related]
19. Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis.
di Nuzzo L; Orlando R; Nasca C; Nicoletti F
Drug Des Devel Ther; 2014; 8():555-68. PubMed ID: 24876766
[TBL] [Abstract][Full Text] [Related]
20. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
Eckstein C; Bhatti MT
Surv Ophthalmol; 2016; 61(3):318-32. PubMed ID: 26703886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
